Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts

A majority of human colon carcinomas coexpress the epidermal growth factor (ECF)-related peptides transforming growth factor alpha (TGF alpha), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGF alpha. AR and CR, We screened the EGF-related (AS MBOs) for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. Tbe MBOs that showed a high in vitro efficacy were then used for in vitro experiments. TGF alpha, AR and CR AS MBOs were able to inhibit the growth of CEO tumor xenografts in nude mice in a dose-dependent manner. Furthermore, the AS MBOs were able to specifically inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more significant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO, Finally, tumors from mice treated with TGF alpha, AR and CR AS MBOs showed a significant reduction of microvessel count, as compared with tumors from untreated mice or from mire treated with a single AS MBO, These data suggest that combinations of AS oligonucleotides directed against different growth factors might represent a novel, experimental therapy approach of colon carcinomas.